Table 2:

NACC Participant Characteristics by Trajectory Group (N=981)

Variable	No Decline	Mild Decline	Moderate Decline	Accelerated Decline
	157(16.0)	307(31.3)	376 (38.3)	141(14.4)
Age at death, y, mean (SD)	85.1 (8.3)	82.2 (9.5)	79.1 (9.1)	76.9 (10.2)
Female sex	69 (44.0)	134 (43.7)	174 (46.3)	77 (54.6)
Race (White)	147 (93.6)	288 (93.8)	353 (93.9)	123 (87.2)
Education, y, mean (SD)	16.5 (2.9)	15.4 (3.1)	15.1 (3.1)	15.3 (3.3)
APOE ε4 allele (≥1 allele)	41 (26.1)	129 (42.0)	215 (57.2)	64 (45.4)
Last Clinical Diagnosis
Normal	74 (47.1)	11 (3.6)	0	0
Impaired/Other	13 (8.3)	4 (1.3)	1 (0.3)	0
MCI	42 (26.8)	31 (10.1)	0	0
Dementia	28 (17.8)	261 (85.0)	375 (99.7)	141 (100.0)
Whole brain, weight (g) mean (SD)	1226.4 (137.8)	1193.6 (164.5)	1136.3 (148.6)	1029.2 (190.7)
Aβ Plaques	129 (82.2)	278 (90.6)	367 (97.6)	136 (96.5)
α-synuclein	31 (19.8)	124 (40.4)	157 (41.8)	68 (48.2)
TDP-43 inclusion bodies	20 (12.7)	70 (22.8)	121 (32.2)	52 (36.9)
Braak NFT stage
I to IV	124 (79.0)	137 (44.6)	58 (15.4)	17 (12.1)
V to VI	33 (21.0)	170 (55.4)	318 (84.6)	124 (87.9)
Cerebral atrophy
None/Mild	109 (69.4)	188 (61.2)	168 (44.7)	23 (16.3)
Moderate/Severe	28 (19.1)	99 (32.3)	189 (50.3)	106 (75.2)
Hippocampal Sclerosis	11 (7.0)	32 (10.4)	73 (19.4)	28 (19.9)
Cerebral amyloid angiopathy
None/Mild	126 (82.9)	216 (70.8)	208 (54.5)	72 (50.7)
Moderate/Severe	25 (16.5)	88 (28.9)	173 (45.3)	70 (49.3)
Atherosclerosis
<50% Occluded	95 (60.5)	200 (65.2)	241 (64.1)	77 (54.6)
≥ 50% Occluded	62 (39.5)	105 (34.2)	132 (35.1)	63 (44.7)
Arteriolosclerosis
None/Mild	91 (58.0)	137 (44.6)	163 (42.7)	48 (34.0)
Moderate/Severe	65 (41.4)	168 (54.7)	214 (56.0)	92 (65.3)
Infarcts/Lacunes
No	99 (63.1)	200 (65.2)	251 (66.8)	106 (75.2)
Yes	57 (36.9)	106 (34.5)	123 (32.7)	35 (24.8)

Mean (SD) or proportion as shown. SD, standard deviation; Abbreviations: NACC, National Alzheimer’s Coordinating Center. APOE, Apolipoprotein E; Aβ, Amyloid-β; TDP, transactive response DNA binding protein; NFT, Neurofibrillary tangles; Missing data are reported in Supplementary Table 2.